Search Results - "Famiglietti, Vincenzo"

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Caputo, Vincenza, De Falco, Vincenzo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Martini, Giulia, Corte, Carminia Maria Della, Ciardiello, Davide, Poliero, Luca, De Vita, Ferdinando, Orditura, Michele, Fasano, Morena, Franco, Renato, Caraglia, Michele, Avitabile, Arianna, Scalamogna, Roberto, Marchi, Beatrice, Ciardiello, Fortunato, Troiani, Teresa, Napolitano, Stefania

“…Background: Recently, new evidence of the next-generation sequencing (NGS) liquid biopsy utility in clinical practice has been developed. This assay is…”
Get full text

Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial by Della Corte, Carminia Maria, Fasano, Morena, Ciaramella, Vincenza, Cimmino, Flora, Cardnell, Robert, Gay, Carl M, Ramkumar, Kavya, Diao, Lixia, Di Liello, Raimondo, Viscardi, Giuseppe, Famiglietti, Vincenzo, Ciardiello, Davide, Martini, Giulia, Napolitano, Stefania, Tuccillo, Concetta, Troiani, Teresa, Martinelli, Erika, Wang, Jing, Byers, Lauren, Morgillo, Floriana, Ciardiello, Fortunato

“…We recently conducted Cetuximab-AVElumab-Lung (CAVE-Lung), a proof-of-concept, translational and clinical trial, to evaluate the combination of two IgG1…”
Get full text

Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis by Diana, Anna, Carlino, Francesca, Buono, Giuseppe, Antoniol, Giuliano, Famiglietti, Vincenzo, De Angelis, Carmine, Carrano, Simone, Piccolo, Antonio, De Vita, Ferdinando, Ciardiello, Fortunato, Daniele, Bruno, Arpino, Grazia, Orditura, Michele

“…In luminal-like early breast cancer (BC), the lack of Progesterone Receptor (PR) expression generally correlates with more aggressive behavior but the clinical…”
Get full text

Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma by De Falco, Vincenzo, Napolitano, Stefania, Franco, Renato, Zito Marino, Federica, Formisano, Luigi, Esposito, Daniela, Suarato, Gabriella, Napolitano, Rossella, Esposito, Alfonso, Caraglia, Francesco, Giugliano, Maria Cristina, Cioli, Eleonora, Famiglietti, Vincenzo, Bianco, Roberto, Argenziano, Giuseppe, Ronchi, Andrea, Ciardiello, Davide, Nardone, Valerio, D'Ippolito, Emma, Del Tufo, Sara, Ciardiello, Fortunato, Troiani, Teresa

“…Cemiplimab has demonstrated relevant clinical activity in cutaneous squamous cell carcinoma (cSCC) but mechanisms of primary and acquired resistance to…”
Get full text

All-in-One Spinal Cord Stimulation in Lymphoproliferative Diseases by Sica, Antonello, Casale, Beniamino, Sagnelli, Caterina, Di Dato, Maria Teresa, Buonavolontà, Pietro, Salzano, Anna Maria, Sagnelli, Evangelista, Famiglietti, Vincenzo, Saracco, Elisabetta, Tammaro, Dario, Papa, Alfonso

“…Even patients with lymphoproliferative diseases may develop a persistent chronic pain not responsive to usual treatments due to changes in antibody production…”
Get full text

Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event by Parente, Paola, Ciardiello, Davide, Reggiani Bonetti, Luca, Famiglietti, Vincenzo, Cazzato, Gerardo, Caramaschi, Stefania, Attino, Vito, Urbano, Diego, Di Maggio, Giuseppe, Ingravallo, Giuseppe

“…Cutaneous metastasis from solid tumors is a rare event and usually represents a late occurrence in the natural history of an advanced visceral malignancy…”
Get full text

Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer by Fasano, Morena, Della Corte, Carminia Maria, Di Liello, Raimondo, Barra, Giusi, Sparano, Francesca, Viscardi, Giuseppe, Iacovino, Maria Lucia, Paragliola, Fernando, Famiglietti, Vincenzo, Ciaramella, Vincenza, Cimmino, Flora, Capasso, Mario, Iolascon, Achille, Sforza, Vincenzo, Morabito, Alessandro, Maiello, Evaristo, Ciardiello, Fortunato, Morgillo, Floriana

“…BackgroundAntibody-dependent cell-mediated cytotoxicity (ADCC) may mediate antitumour activity of IgG1-isotype monoclonal antibody (mAb), suggesting as…”
Get full text

Chronic Chest Pain Control after Trans-Thoracic Biopsy in Mediastinal Lymphomas by Sica, Antonello, Casale, Beniamino, Sagnelli, Caterina, Di Dato, Maria Teresa, Rispoli, Marco, Santagata, Mario, Buonavolontà, Pietro, Fiorelli, Alfonso, Vitiello, Paola, Caccavale, Stefano, Creta, Massimiliano, Salzano, Anna Maria, Sagnelli, Evangelista, Saracco, Elisabetta, Gazzerro, Giuseppe, Famiglietti, Vincenzo, Tammaro, Dario, Papa, Alfonso

“…Chest pain following a trans-thoracic biopsy often has multiple etiologies, especially in patients with lymphomas. Pathological neuronal mechanisms integrate…”
Get full text

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab by Martini, Giulia, Ciardiello, Davide, Dallio, Marcello, Famiglietti, Vincenzo, Esposito, Lucia, Corte, Carminia Maria Della, Napolitano, Stefania, Fasano, Morena, Gravina, Antonietta Gerarda, Romano, Marco, Loguercio, Carmelina, Federico, Alessandro, Maiello, Evaristo, Tuccillo, Concetta, Morgillo, Floriana, Troiani, Teresa, Di Maio, Massimo, Martinelli, Erika, Ciardiello, Fortunato

“…Gut microbiota is involved in immune modulation and immune checkpoint inhibitors (ICIs) efficacy. Single‐arm phase II CAVE‐mCRC and CAVE‐LUNG clinical trials…”
Get full text

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial by Martinelli, Erika, Martini, Giulia, Famiglietti, Vincenzo, Troiani, Teresa, Napolitano, Stefania, Pietrantonio, Filippo, Ciardiello, Davide, Terminiello, Marinella, Borrelli, Carola, Vitiello, Pietro Paolo, De Braud, Filippo, Morano, Federica, Avallone, Antonio, Normanno, Nicola, Nappi, Anna, Maiello, Evaristo, Latiano, Tiziana, Falcone, Alfredo, Cremolini, Chiara, Rossini, Daniele, Santabarbara, Giuseppe, Pinto, Carmine, Santini, Daniele, Cardone, Claudia, Zanaletti, Nicoletta, Di Liello, Alessandra, Renato, Daniela, Esposito, Lucia, Marrone, Francesca, Ciardiello, Fortunato

“…Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic…”
Get more information

Real‐world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions by De Falco, Vincenzo, Suarato, Gabriella, Napolitano, Rossella, Argenziano, Giuseppe, Famiglietti, Vincenzo, Amato, Annarita, Servetto, Alberto, Bianco, Roberto, Formisano, Luigi, Terrano, Vincenzo, Esposito, Alfonso, Giugliano, Maria Cristina, Ciardiello, Davide, Ciardiello, Fortunato, Napolitano, Stefania, Troiani, Teresa

“…Adjuvant immunotherapy (IO) and targeted therapy (TT) have improved relapse‐free survival (RFS) in patients with stage III melanoma, although about 25% of them…”
Get full text

Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial by Napolitano, Stefania, Ciardiello, Davide, De Falco, Vincenzo, Martini, Giulia, Martinelli, Erika, Della Corte, Carminia Maria, Esposito, Lucia, Famiglietti, Vincenzo, Di Liello, Alessandra, Avallone, Antonio, Cardone, Claudia, De Stefano, Alfonso, Montesarchio, Vincenzo, Zampino, Maria Giulia, Fazio, Nicola, Di Maio, Massimo, Del Tufo, Sara, De Vita, Ferdinando, Altucci, Lucia, Marrone, Francesca, Ciardiello, Fortunato, Troiani, Teresa

“…The randomized phase II VELO trial showed that the addition of panitumumab to trifluridine/tipiracil significantly improves progression‐free survival (PFS) as…”
Get full text

Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival by Ciardiello, Davide, Famiglietti, Vincenzo, Napolitano, Stefania, Esposito, Lucia, Pietrantonio, Filippo, Avallone, Antonio, Maiello, Evaristo, Cremolini, Chiara, Troiani, Teresa, Martinelli, Erika, Ciardiello, Fortunato, Martini, Giulia

“…High neutrophil-to-lymphocyte ratio (NLR) is a poor prognostic factor in metastatic colorectal cancer (mCRC). Here we provide final results of CAVE mCRC trial,…”
Get full text

HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study by Carlino, Francesca, Diana, Anna, Ventriglia, Anna, Piccolo, Antonio, Mocerino, Carmela, Riccardi, Ferdinando, Bilancia, Domenico, Giotta, Francesco, Antoniol, Giulio, Famiglietti, Vincenzo, Feliciano, Salvatore, Cangiano, Rodolfo, Lobianco, Lorenzo, Pellegrino, Benedetta, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele

“…Background: Approximately 45–50% of breast cancers (BCs) have a HER2 immunohistochemical score of 1+ or 2+ with negative in situ hybridization, defining the…”
Get full text

Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer by Ciardiello, Davide, Martini, Giulia, Famiglietti, Vincenzo, Napolitano, Stefania, De Falco, Vincenzo, Troiani, Teresa, Latiano, Tiziana Pia, Ros, Javier, Elez Fernandez, Elena, Vitiello, Pietro Paolo, Maiello, Evaristo, Ciardiello, Fortunato, Martinelli, Erika

“…The prognosis of patients with metastatic colorectal cancer (mCRC) who progressed to the first and the second lines of treatment is poor. Thus, new therapeutic…”
Get full text

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF V600E-Mutant Colorectal Cancer by Napolitano, Stefania, Woods, Melanie, Lee, Hey Min, De Falco, Vincenzo, Martini, Giulia, Della Corte, Carminia Maria, Martinelli, Erika, Famiglietti, Vincenzo, Ciardiello, Davide, Anderson, Amanda, Fowlkes, Natalie Wall, Villareal, Oscar Eduardo, Sorokin, Alexey, Kanikarla, Preeti, Coker, Olu, Morris, Van, Altucci, Lucia, Tabernero, Josep, Troiani, Teresa, Ciardiello, Fortunato, Kopetz, Scott

“…Abstract Purpose: Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC). However,…”
Get full text

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer by Napolitano, Stefania, Woods, Melanie, Lee, Hey Min, De Falco, Vincenzo, Martini, Giulia, Della Corte, Carminia Maria, Martinelli, Erika, Famiglietti, Vincenzo, Ciardiello, Davide, Anderson, Amanda, Fowlkes, Natalie Wall, Villareal, Oscar Eduardo, Sorokin, Alexey, Kanikarla, Preeti, Coker, Olu, Morris, Van, Altucci, Lucia, Tabernero, Josep, Troiani, Teresa, Ciardiello, Fortunato, Kopetz, Scott

“…Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC). However, there is a need to…”
Get full text

Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial by Napolitano, Stefania, De Falco, Vincenzo, Martini, Giulia, Esposito, Lucia, Famiglietti, Vincenzo, Martinelli, Erika, Ciardiello, Davide, Marrone, Francesca, Avallone, Antonio, Cardone, Claudia, De Stefano, Alfonso, Montesarchio, Vincenzo, Zampino, M. Giulia, Bordonaro, Roberto, Scartozzi, Mario, Santini, Daniele, Di Maio, Massimo, Ciardiello, Fortunato, Troiani, Teresa

“…129 Background: Rechallenge therapy with epidermal growth factor receptor (EGFR) inhibitors in chemo-refractory metastatic colorectal cancer (mCRC) is an…”
Get full text

Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data by Vitale, Pasquale, Zanaletti, Nicoletta, Famiglietti, Vincenzo, De Falco, Vincenzo, Cervantes, Andres, Rosellò, Susanna, Fenocchio, Elisabetta, Milanesio, Michela, Lombardi, Pasquale, Ciardiello, Davide, Martini, Giulia, Martinelli, Erika, Ciardiello, Fortunato, Troiani, Teresa, Napolitano, Stefania

“…There have been significant developments in colorectal cancer (CRC) research over the last few years, with the introduction of new agents that have been…”
Get full text

Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials by Ciardiello, Davide, Napolitano, Stefania, Famiglietti, Vincenzo, Esposito, Lucia, De Falco, Vincenzo, Di Liello, Alessandra, Avallone, Antonio, Maiello, Evaristo, Pietrantonio, Filippo, Cremolini, Chiara, Zampino, Maria Giulia, Fazio, Nicola, Troiani, Teresa, Martinelli, Erika, Ciardiello, Fortunato, Martini, Giulia

“…Rechallenge with anti-EGFR drugs represents a promising strategy in refractory / wild-type (WT) metastatic colorectal cancer (mCRC). We performed the pooled…”
Get full text